Author: Bruminhent, J.; Boongird, S.; Assanatham, M.; Kiertiburanakul, S.; Malathum, K.; Nongnuch, A.; Phuphuakrat, A.; Chaumdee, P.; Jirasiritham, S.; Janphram, C.; Tossiri, S.; Upama, S.; Sethaudom, C.
Title: SARS-CoV-2-specific Humoral Immune Responses after A Single Dose of Inactivated Whole-virus SARS-CoV-2 Vaccine in Kidney Transplant Recipients: An Initial Report Cord-id: c1rn3sfb Document date: 2021_7_22
ID: c1rn3sfb
Snippet: We presented an initial pilot study report focused on immunogenicity and safety following an inactivated whole virus severe acute respiratory syndrome coronavirus 2 vaccination among kidney transplant (KT) recipients. At four weeks after the first dose of vaccine, the level of anti RBD IgG antibody was not significantly different compared to before vaccination in 30 KT recipients (p = 0.45). Moreover, a significant lower mean (95% CI) anti RBD IgG antibody was observed compared to 30 immunocompe
Document: We presented an initial pilot study report focused on immunogenicity and safety following an inactivated whole virus severe acute respiratory syndrome coronavirus 2 vaccination among kidney transplant (KT) recipients. At four weeks after the first dose of vaccine, the level of anti RBD IgG antibody was not significantly different compared to before vaccination in 30 KT recipients (p = 0.45). Moreover, a significant lower mean (95% CI) anti RBD IgG antibody was observed compared to 30 immunocompetent controls (2.4 [95% CI 1.3 to 3.5] vs. 173.1 [95% CI 88.3-2,457.9] AU/mL, p < 0.001). Mild adverse events included fever (17%) and localized pain at the injection site (14%) were observed after vaccination.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date